Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NEWS -- Plus Therapeutics to Present at BIO CEO & Investor Conference
AUSTIN, Texas, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics, will present a company overview during the BIO CEO & Investor Conference on Monday, February 14, 2022 at 1:15 p.m. ET, at the New York Marriott Marquis.
The Company’s live presentation will be made available through the BIO CEO & Investor Conference website and available on-demand to registered participants during the conference at https://www.bio.org/events/bio-ceo-investor-conference/sessions. Investors interested in arranging a meeting with the Company’s management for this conference should contact the conference coordinator.
About Plus Therapeutics
Plus Therapeutics (Nasdaq: PSTV) is a clinical-stage pharmaceutical company focused on developing innovative, targeted radiotherapeutics for adults and children worldwide with rare and difficult-to-treat cancers. Our proprietary radiotherapeutic platform uniquely uses nanoliposomes to encapsulate and deliver the radioisotope, Rhenium, into or near a tumor via a single, direct infusion. The lead radiotherapeutic in our pipeline, Rhenium-186 NanoLiposome (186RNL), is being evaluated in U.S. multi-center clinical trials for the treatment of recurrent glioblastoma and leptomeningeal metastases. More information may be found at https://PlusTherapeutics.com and https://ReSPECT-Trials.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “designed to,” “will,” “can,” “potential,” “focus,” “preparing,” “next steps,” “possibly,” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the potential promise of 186RNL including the ability of 186RNL to safely and effectively deliver radiation directly to the tumor at high doses; expectations as to the Company’s future performance including the next steps in developing the Company’s current assets; the Company’s clinical trials including statements regarding the timing and characteristics of the ReSPECT-LM or the ReSPECT-PBC trials; possible negative effects of 186RNL; the continued evaluation of 186RNL including through evaluations via a seventh patient cohort; and the intended functions of the Company’s platform and expected benefits from such functions.
The forward-looking statements included in this press release are subject to a number of risks and uncertainties that may cause actual results to differ materially from those discussed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the Company’s actual results may differ, including materially, from those anticipated in these forward-looking statements as a result of various factors, including, but not limited to, the following: the early stage of the Company’s product candidates and therapies, the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash, the outcome of the Company’s partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it, market conditions, product performance, litigation or potential litigation, and competition within the regenerative medicine field, among others; and additional risks described under the heading “Risk Factors” in the Company’s Securities and Exchange Commission filings, including in the Company’s annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.
Investor Contact
Peter Vozzo
ICR Westwicke
(443) 377-4767
mailto://Peter.Vozzo@westwicke.com
Media Contact
Terri Clevenger
ICR Westwicke
(203) 856-4326
mailto://Terri.Clevenger@westwicke.com
NEWS -- FuelPositive Issues Statement About Unsanctioned and Misleading Promotional Activity Concerning Its Common Stock
TORONTO, Feb. 04, 2022 (GLOBE NEWSWIRE) -- FuelPositive Corporation (TSX.V: NHHH) (OTCQB: NHHHF) (the “Company”) is informing its investors of unsanctioned, misleading and potentially manipulative stock promotion being conducted by unidentified third parties. The Company became aware of some misleading promotional material on February 3, 2022. The Company is not aware, however, of the full nature and content of the promotional activity, the extent of the dissemination, or who is behind it. The Company is actively investigating the matter.
“There has been some misleading anonymous third-party promotion that has come to our attention. It is not sanctioned or sponsored by FuelPositive and the information should not be relied upon. It has not affected our trading activity, however we felt it was important to advise investors that it is going on. We are taking this action to protect our reputation and to prevent investors from being misled,” said Ian Clifford, FuelPositive Chief Executive Officer and Board Chair.
FuelPositive has an ongoing agreement for investor relations services with RB Milestone Group, which has been identified on the Company’s website (https://fuelpositive.com/leadership/) and is registered with the TSX Venture Exchange and the OTCQB.
“We are not saying that all third-party content should not be relied upon, as there is positive and balanced media coverage that we want to encourage. But we cannot assure the accuracy of information published by third parties. Investors should only make decisions based on the advice of registered advisors,” added Clifford.
About FuelPositive
FuelPositive is a Canadian growth-stage technology company committed to providing commercially viable and sustainable “cradle to cradle” clean technology solutions, including green ammonia (NH3), for use across a broad spectrum of industries and applications.
By focusing on technologies that are clean and economically advantageous/realizable, the Company aims to change the course of climate change through practical solutions that can be implemented now.
The Company’s core technology, a modular and scalable green ammonia system, takes air, water and sustainable electricity and synthesizes it into a non-polluting chemical for multiple applications, including fertilizer for farming, fuel for internal combustion engines and a solution for grid storage. Green ammonia is being considered as a replacement for fossil fuels and as a key enabler of the hydrogen economy.
The Company’s most recent corporate update, presented in November, can be found here (https://fuelpositive.com/reports-and-publications/).
Cautionary Statement
Trading in the securities of the Company should be considered highly speculative. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains certain “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) that are based on expectations, estimates and projections as at the date of this news release. The information in this release about future plans and objectives of the Company, including the expected expenditures of the proceeds of the private placement, are forward-looking statements. These forward-looking statements are based on assumptions and estimates of management of the Company at the time they were made and involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect.
Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
Forward-looking information is provided for the purpose of providing information about management’s expectations and plans relating to the future. The Company disclaims any intention or obligation to update or revise any forward-looking information or to explain any material difference between subsequent actual events and such forward-looking information, except to the extent required by applicable law.
For Media or Investor enquiries, please contact:
Ian Clifford
Chief Executive Officer and Board Chair
mailto://mailbox1@fuelpositive.com
https://www.fuelpositive.com
Investor Relations (United States)
RBMG – RB Milestone Group LLC
Trevor Brucato, Managing Director
mailto://fuelpositive@rbmilestone.com
https://www.rbmilestone.com
It's going to take 1 billion to build that, do they have enough shares to sell and or who will lend them the money to build it and how long will it take to pay back the loan, and does anyone believe it will happen in 36 months per the Press release.
NEWS -- Navidea Biopharmaceuticals Announces Settlement of Platinum Litigation; Receipt of Noncompliance Notice from NYSE American
DUBLIN, Ohio, February 03, 2022--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced settlement of the ongoing litigation with Platinum-Montaur Life Sciences LLC ("Platinum-Montaur"), an affiliate of Platinum Management (NY) LLC, Platinum Partners Value Arbitrage Fund L.P., Platinum Partners Capital Opportunity Fund, Platinum Partners Liquid Opportunity Master Fund L.P., Platinum Liquid Opportunity Management (NY) LLC, and Montsant Partners LLC (collectively, "Platinum").
As disclosed in the notes to the financial statements included in the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, the Company has been engaged in litigation with Platinum-Montaur, in which Platinum-Montaur was seeking damages of approximately $1.9 million plus interest. On January 13, 2022, Navidea and Platinum executed a Joint Settlement, Release and Confidentiality Agreement (the "Settlement Agreement"). As a result of the Settlement Agreement, Platinum has dismissed their claims against the Company thereby ending the litigation between the parties.
NYSE American Compliance Letter
On January 28, 2022, Navidea received a letter from NYSE American LLC ("NYSE American" or the "Exchange") stating that Navidea was not in compliance with the continued listing standards as set forth in Section 1003(a)(iii) of the NYSE American Company Guide (the "Company Guide"). In order to maintain its listing, the Company must submit a plan of compliance by February 27, 2022 addressing how it intends to regain compliance with Section 1003(a)(iii) of the Company Guide by July 28, 2023. If the plan is accepted, the Company may be able to continue its listing but will be subject to periodic reviews by the Exchange. If the Company does not submit a plan or if the plan is not accepted, delisting proceedings will commence. If the plan is accepted but the Company is not in compliance with the continued listing standards by July 28, 2023, or if the Company does not make progress consistent with the plan, the Exchange may initiate delisting procedures. The Company's management is pursuing options to address the deficiency and intends to submit a compliance plan on or before the deadline set by the Exchange.
Navidea’s common stock, par value $0.001 per share ("Common Stock") will continue to be listed on the NYSE American while it attempts to regain compliance with the listing standard noted, subject to Navidea’s compliance with other continued listing requirements. The Common Stock will continue to trade under the symbol "NAVB," but will have an added designation of ".BC" to indicate that Navidea is not in compliance with the NYSE American’s listing standards. The NYSE American notification does not affect Navidea’s business operations or its SEC reporting requirements and does not conflict with or cause an event of default under any of Navidea’s material agreements.
About Navidea
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manocept™ platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea’s Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company’s pipeline through global partnering and commercialization efforts. For more information, please visit https://www.navidea.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business. Forward-looking statements include our expectations regarding pending litigation and other matters. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things: our history of operating losses and uncertainty of future profitability; the final outcome of any pending litigation; our ability to successfully complete research and further development of our drug candidates; the timing, cost and uncertainty of obtaining regulatory approvals of our drug candidates; our ability to successfully commercialize our drug candidates; dependence on royalties and grant revenue; our ability to implement our growth strategy; anticipated trends in our business; our limited product line and distribution channels; advances in technologies and development of new competitive products; our ability to comply with the NYSE American continued listing standards; our ability to maintain effective internal control over financial reporting; the impact of the current coronavirus pandemic; and other risk factors detailed in our most recent Annual Report on Form 10-K and other SEC filings. You are urged to carefully review and consider the disclosures found in our SEC filings, which are available at www.sec.gov or at http://ir.navidea.com.
Investors are urged to consider statements that include the words "will," "may," "could," "should," "plan," "continue," "designed," "goal," "forecast," "future," "believe," "intend," "expect," "anticipate," "estimate," "project," and similar expressions, as well as the negatives of those words or other comparable words, to be uncertain forward-looking statements.
You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be incorrect. We undertake no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this report. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially from those anticipated or implied in the forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220203005915/en/
Contacts
Investor Relations Contact
Navidea Biopharmaceuticals, Inc.
Jeffrey Smith
Vice President of Operations
614-822-2365
mailto://jsmith@navidea.com
NEWS -- FuelPositive Corp. Featured in Syndicated Broadcast Covering Filing of Annual Audited Financial Statements and Release of Corporate Update
LOS ANGELES, Feb. 03, 2022 (GLOBE NEWSWIRE) -- via InvestorWire — FuelPositive Corp. (TSX.V: NHHH) (OTCQB: NHHHF), a growth stage company focused on licensing, partnership and acquisition opportunities building upon various technological achievements, today announces that it has been featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The audio news release covers FuelPositive’s recent corporate update and announcement that it has filed its annual audited financial statements and accompanying management’s discussion and analysis for the year ended September 30, 2021.
To hear the audio production, visit: https://nnw.fm/sdSiA
To read the original press release, visit: https://nnw.fm/tiTzq
As detailed in the news release, construction of the first demonstration units for FuelPositive’s green ammonia production system is progressing to plan. The on-site system comprises a nitrogen generator to produce nitrogen from air, a water electrolyser to produce hydrogen from water, and a patent-pending green ammonia synthesis reactor to produce ammonia from the hydrogen and nitrogen. FuelPositive expects to begin validation in the first half of 2022 to meet its target plan for the first demonstration pilot project.
“FuelPositive is moving forward at full speed to commercialize our in situ, modular, scalable and transportable green ammonia production system,” Nelson Leite, Chief Operating Officer of FuelPositive, stated in the news release. “As the weeks go by, the world is becoming increasingly excited about the potential of green ammonia to decarbonize our industries, offer control and energy independence to consumers and provide food security for our future. Our technology is by far the best we have seen and offers a unique approach, placing clean tech production on the sites where the green ammonia will be used. No greenhouse gas emissions, and no faulty and fluctuating supply chain. It’s an affordable and practical solution and we are poised to deliver.”
A 6,000-acre grain and plant-based farm in Manitoba has been selected for the first demonstration pilot project. Manitoba is ideal because of its green electricity grid and because it will allow the company to test the production unit in the harsh Canadian climate, with its long, cold winters and hot summers. According to FuelPositive CEO and Chair Ian Clifford, the company is on track to deliver its first prototype in Manitoba in late summer 2022.
FuelPositive recently conducted its first site visit at the farm, which is equipped with solar power and has grid access to Manitoba hydro power, and the team is now finalizing an agreement with the farmer. Per the update, the farmer intends to start out producing fertilizer but plans to expand to use green ammonia as a fuel for grain drying. They are also keenly interested in converting their tractors and other internal combustion engines to be completely carbon-free, running on FuelPositive green ammonia produced on the farm.
About FuelPositive Corp.
FuelPositive Corp. is a Canadian growth-stage technology company committed to providing commercially viable and sustainable, “cradle to cradle”, clean energy solutions, including carbon-free ammonia (NH3), for use across a broad spectrum of industries and applications. By focusing on technologies that are clean, economically advantageous/realizable and that leverage existing infrastructure, the company aims to change the course of climate change through practical solutions that can be implemented now. For more information, visit the company’s website at https://www.FuelPositive.com
About NetworkNewsAudio
NetworkNewsAudio (“NNA”), one of 50+ brands within IBN (InvestorBrandNetwork), allows you to sit back and listen to market updates, CEO interviews and AudioPressRelease (“APR”) productions. These audio clips provide snapshots of position, opportunity and momentum. NNA can assist by cutting through the overload of information in today's market, while bringing its clients unparalleled visibility, recognition and brand awareness. IBN is where news, content and information converge. IBN is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, IBN has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public with an ever-growing distribution network of 5,000+ key syndication outlets across the nation.
For more information, visit: https://www.NetworkNewsAudio.com
Please see full terms of use and disclaimers on the IBN website applicable to all content provided by IBN, wherever published or re-published: https://IBN.fm/Disclaimer
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.
Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
https://www.InvestorBrandNetwork.com
310.299.1717 Office
mailto://Editor@InvestorBrandNetwork.com
NEWS -- Heat Biologics Announces Planned Transfer to the NYSE American
DURHAM, N.C., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, announced today that it plans to change its listing from the Nasdaq Capital Market to the NYSE American stock exchange.
“We are pleased to announce our listing on the NYSE American, a global leader in listings for a range of sectors, including life sciences and technology,” said Jeff Wolf, Chairman and Chief Executive Officer of Heat. “As our company continues to grow and execute on upcoming milestones, we believe our stockholders will benefit from the broad exposure and international reach of this exchange.”
Heat expects to commence trading as an NYSE American-listed company when markets open on Monday, February 14, 2022. The Company’s common stock will continue to trade under its existing “HTBX” symbol. The Company will continue to trade on the Nasdaq Capital Market until the close of market on Friday, February 11, 2022.
About Heat Biologics, Inc.
Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies and vaccines to modulate the immune system. Heat’s gp96 platform is designed to activate immune responses against cancer or infectious diseases. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in a Phase 2 trial, various infectious disease/biological threat programs in preclinical development and a pipeline of proprietary immunomodulatory antibodies and cell-based therapies, including PTX-35 and HS-130 in Phase 1 clinical trials.
Forward-Looking Statements
This release includes forward-looking statements that are within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are identified by certain words or phrases such as "may", "will", "aim", "will likely result", "believe", "expect", "will continue", "anticipate", "estimate", "intend", "plan", "contemplate", "seek to", "future", "objective", "goal", "project", "should", "will pursue" and similar expressions or variations of such expressions. These forward-looking statements reflect the Company's current expectations about its future plans and performance and includes statements regarding the timing of the change of its listing to the NYSE American stock. These forward-looking statements rely on a number of assumptions and estimates which could be inaccurate and which are subject to risks and uncertainties. Actual results could vary materially from those anticipated or expressed in any forward-looking statement made by the Company. Please refer to the Company's most recent annual report on Form 10-K filed with the SEC and other subsequent filings with the SEC for a further discussion of these risks and uncertainties. The information in this release is provided only as of the date of this release, and Heat undertakes no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.
Media and Investor Relations Contact
David Waldman
+1 919 289 4017
mailto://investorrelations@heatbio.com
NEWS -- Oncolytics Biotech® Provides Positive Safety Update on the Pancreatic Cancer Cohort of its Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial
Independent safety review completed with no toxicity concerns
Cohort builds on prior proof-of-concept data demonstrating clinical benefit of pelareorep-checkpoint inhibitor combination in pancreatic cancer
Multi-indication trial being conducted in collaboration with Roche and AIO also includes cohorts in metastatic colorectal and advanced anal cancers
SAN DIEGO and CALGARY, AB, Feb. 2, 2022 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the successful completion of the three-patient safety run-in for the pancreatic cancer cohort of the phase 1/2 GOBLET study following evaluation by the study's Data Safety Monitoring Board (DSMB). The DSMB noted no safety concerns in these patients and recommended the study proceed as planned. The safety run-in for the trial's third-line metastatic colorectal cancer cohort remains ongoing.
The GOBLET study is being managed by AIO, a leading academic cooperative medical oncology group based in Germany, and is designed to evaluate the safety and efficacy of pelareorep in combination with Roche's anti-PD-L1 checkpoint inhibitor atezolizumab in patients with metastatic pancreatic, metastatic colorectal, and advanced anal cancers. The study remains ongoing and is expected to enroll patients at 14 clinical trial sites across Germany.
"This positive safety evaluation adds to a robust body of evidence demonstrating the favorable safety profile of pelareorep-checkpoint inhibitor combinations across multiple indications," said Thomas Heineman, M.D., Ph.D., Chief Medical Officer of Oncolytics. "It also represents an important step in the development of these combinations for the treatment of pancreatic cancer and builds on prior clinical proof-of-concept data in this indication. These data highlight the potential of pelareorep to benefit patients with pancreatic and other gastrointestinal cancers by reversing immunosuppressive tumor microenvironments that limit the effectiveness of checkpoint inhibitors. We believe adding pelareorep to treatment regimens will improve clinical response rates in these patients, and we look forward to evaluating this hypothesis through successfully advancing the GOBLET study."
The GOBLET study's pancreatic cancer cohort extends previously reported clinical data demonstrating the synergy and anti-cancer activity of pelareorep combined with checkpoint inhibition in pancreatic cancer patients who progressed after first-line treatment (link to PR (https://www.oncolyticsbiotech.com/press-releases/press-releases/detail/541/oncolytics-biotech-announces-clinical-and-biomarker-data), link to poster (https://d1io3yog0oux5.cloudfront.net/_6fbc2aab61c569b67df26fcb0b81d15b/oncolyticsbiotech/db/343/2562/pdf/ASCO+2021_final.pdf)). It also builds on prior early clinical data that showed a greater than 80% increase in median progression-free survival in pancreatic cancer patients with low levels of CEACAM6 expression who received pelareorep in combination with chemotherapy (link to PR (https://ir.oncolyticsbiotech.com/press-releases/detail/494/oncolytics-biotech-announces-statistically-significant), link to poster (https://d1io3yog0oux5.cloudfront.net/_6b48a135651525a703eef6c0b666cf11/oncolyticsbiotech/db/343/2513/pdf/2020+-+ASCO+GI+-+Noonan+-+CEACAM6+is+a+candidate+biomarker+for+Reolysin%C2%AE+(pelareorep)+sensitivity+in+pancreatic+adenocarcinoma+(PDAC).pdf)). In addition to evaluating the safety and efficacy of pelareorep-atezolizumab treatment, GOBLET also seeks to demonstrate the potential of CEACAM6 and T cell clonality as predictive biomarkers, which may increase the likelihood of success of future registrational studies by allowing selection of the most appropriate patients.
About GOBLET
The GOBLET (Gastrointestinal tumOrs exploring the treatment comBinations with the oncolytic reovirus peLarEorep and anTi-PD-L1) study is a phase 1/2 multiple indication study in advanced or metastatic gastrointestinal tumors. The study is being conducted at 14 centers in Germany. The co-primary endpoints of the study are objective response rate (ORR) assessed at week 16 and safety. Key secondary and exploratory endpoints include additional efficacy assessments and evaluation of potential biomarkers (T cell clonality and CEACAM6). The study employs a Simon two-stage design with Stage 1 comprising four treatment groups expected to enroll a total of approximately 55 patients:
NEWS -- Tokens.com Announces Change of Auditor
TORONTO, February 01, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or "the Company"), announces that its board of directors (the "Board"), has approved a change of the Company’s auditor. The Board and the Audit Committee of the Board have appointed DNTW Toronto LLP (the "Incoming Auditor") as the Company’s new auditor, effective as of January 28, 2022. As a result, the Company’s former auditor, Manning Elliott LLP (the "Former Auditor"), has submitted its resignation, effective January 28, 2022.
"We are grateful for the services provided by Manning Elliott since 2020," said Andrew Kiguel, CEO of Tokens.com, "and look forward to a smooth transition with the DNTW Toronto team and continuing to deliver on our strategic objectives."
There were no disagreements or unresolved issues with the Former Auditor on any matter of the audit scope or procedures, accounting principles or policies, or financial statement disclosure. There have been no "reportable events" (as defined in National Instrument 51-102 – Continuous Disclosure Obligations) between the Company and the Former Auditor. The Former Auditor did not provide a modified opinion in their auditor’s report for the financial statements of the Company fiscal year ended December 31, 2020.
A Notice of Change of Auditor (the "Notice"), together with the response letters from the Former Auditor and Incoming Auditor have been reviewed by the Audit Committee and the Board and have been filed on https://www.sedar.com.
About Tokens.com
Tokens.com Corp is a publicly traded Web3 company that owns an inventory of Metaverse, Decentralized Finance ("DeFi"), Non-Fungible Tokens ("NFT") and Play-to-Earn Gaming ("P2E") based digital assets. Tokens.com is the majority owner of Metaverse Group, one of the world’s first virtual real estate companies. Hulk Labs, a wholly-owned Tokens.com subsidiary, focuses on investing in P2E revenue generating tokens and NFTs. Additionally, Tokens.com owns and stakes crypto assets to earn additional tokens. Through its growing digital assets and NFTs, Tokens.com provides public market investors with a simple and secure way to gain exposure to Web3.
For further information please visit https://Tokens.com
Keep up-to-date on Tokens.com developments and join our online communities at Twitter, LinkedIn, and YouTube.
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220201006122/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
Telephone: +1-647-578-7490
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Media Contact: Ryleigh Ebron – Talk Shop Media
Email: mailto://ryleigh@talkshopmedia.com
NEWS -- Tokens.com Announces Change of Auditor
TORONTO, February 01, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or "the Company"), announces that its board of directors (the "Board"), has approved a change of the Company’s auditor. The Board and the Audit Committee of the Board have appointed DNTW Toronto LLP (the "Incoming Auditor") as the Company’s new auditor, effective as of January 28, 2022. As a result, the Company’s former auditor, Manning Elliott LLP (the "Former Auditor"), has submitted its resignation, effective January 28, 2022.
"We are grateful for the services provided by Manning Elliott since 2020," said Andrew Kiguel, CEO of Tokens.com, "and look forward to a smooth transition with the DNTW Toronto team and continuing to deliver on our strategic objectives."
There were no disagreements or unresolved issues with the Former Auditor on any matter of the audit scope or procedures, accounting principles or policies, or financial statement disclosure. There have been no "reportable events" (as defined in National Instrument 51-102 – Continuous Disclosure Obligations) between the Company and the Former Auditor. The Former Auditor did not provide a modified opinion in their auditor’s report for the financial statements of the Company fiscal year ended December 31, 2020.
A Notice of Change of Auditor (the "Notice"), together with the response letters from the Former Auditor and Incoming Auditor have been reviewed by the Audit Committee and the Board and have been filed on https://www.sedar.com.
About Tokens.com
Tokens.com Corp is a publicly traded Web3 company that owns an inventory of Metaverse, Decentralized Finance ("DeFi"), Non-Fungible Tokens ("NFT") and Play-to-Earn Gaming ("P2E") based digital assets. Tokens.com is the majority owner of Metaverse Group, one of the world’s first virtual real estate companies. Hulk Labs, a wholly-owned Tokens.com subsidiary, focuses on investing in P2E revenue generating tokens and NFTs. Additionally, Tokens.com owns and stakes crypto assets to earn additional tokens. Through its growing digital assets and NFTs, Tokens.com provides public market investors with a simple and secure way to gain exposure to Web3.
For further information please visit https://Tokens.com
Keep up-to-date on Tokens.com developments and join our online communities at Twitter, LinkedIn, and YouTube.
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220201006122/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
Telephone: +1-647-578-7490
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Media Contact: Ryleigh Ebron – Talk Shop Media
Email: mailto://ryleigh@talkshopmedia.com
NEWS -- Tokens.com Purchases CryptoPunk #5067
TORONTO, February 01, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or "the Company"), a publicly-traded company that invests in crypto assets linked to the Metaverse, Decentralized Finance ("DeFi"), Non-Fungible Tokens ("NFTs") and Play-to-Earn Gaming ("P2E"), is pleased to share that its wholly-owned subsidiary company, Hulk Labs, has purchased CryptoPunk #5067 to add to its NFT collection.
CryptoPunks are 10,000 human, Zombie, Ape and Alien avatars, algorithmically generated with unique traits, launched in 2017 from Lava Labs. CryptoPunks are recognized as one of the first NFT collections that inspired the ERC721 standard and the concept of NFTs on Ethereum. Celebrities such as Jason Derulo, Jay-Z, Gary Vaynerchuk, football player Odell Beckham Jr, Snoop Dogg, Serena Williams, and companies such as Visa have all collected CryptoPunks.
CryptoPunk #5067 features a female from the icon Larva Labs collection with the following traits: 1 of 147 Red Mohawks, Classic Shades and an Earring. Hulk Labs plans to stake the NFT on NFTX vaults to earn income from this asset. CryptoPunks are a mature asset class, having completed over $2 Billion Dollars in volume to-date.
"Tokens.com is one of the only publicly traded companies to hold its own CryptoPunk," said Andrew Kiguel, CEO of Tokens.com. "Since CryptoPunks can now be staked, we have the ability to own this unique asset class and also generate recurring revenue from it. This is in line with our philosophy of holding crypto assets that can appreciate in value and generate income."
About Hulk Labs
Hulk Labs is a Tokens.com subsidiary company that invests in the NFT ecosystem with a focus on play-to-earn games. The Company acquires gaming tokens and NFTs and monetizes them through staking and gaming guilds. For further information please visit https://tokens.com.
About Tokens.com
Tokens.com Corp is a publicly traded Web3 company that owns an inventory of Metaverse, P2E, DeFi and NFT based digital assets. Tokens.com is the majority owner of Metaverse Group, one of the world’s first virtual real estate companies. Hulk Labs, a wholly-owned Tokens.com subsidiary, focuses on investing in Play-to-Earn revenue generating gaming tokens and NFTs. Additionally, Tokens.com owns and stakes crypto assets to earn additional tokens. Through its growing digital assets and NFTs, Tokens.com provides public market investors with a simple and secure way to gain exposure to Web3.
Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities at Twitter, LinkedIn, and YouTube.
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at https://www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220201005359/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
+1-647-578-7490
mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
mailto://contact@tokens.com
Media: Ryleigh Ebron – Talk Shop Media
mailto://ryleigh@talkshopmedia.com
NEWS -- Tokens.com Purchases CryptoPunk #5067
TORONTO, February 01, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or "the Company"), a publicly-traded company that invests in crypto assets linked to the Metaverse, Decentralized Finance ("DeFi"), Non-Fungible Tokens ("NFTs") and Play-to-Earn Gaming ("P2E"), is pleased to share that its wholly-owned subsidiary company, Hulk Labs, has purchased CryptoPunk #5067 to add to its NFT collection.
CryptoPunks are 10,000 human, Zombie, Ape and Alien avatars, algorithmically generated with unique traits, launched in 2017 from Lava Labs. CryptoPunks are recognized as one of the first NFT collections that inspired the ERC721 standard and the concept of NFTs on Ethereum. Celebrities such as Jason Derulo, Jay-Z, Gary Vaynerchuk, football player Odell Beckham Jr, Snoop Dogg, Serena Williams, and companies such as Visa have all collected CryptoPunks.
CryptoPunk #5067 features a female from the icon Larva Labs collection with the following traits: 1 of 147 Red Mohawks, Classic Shades and an Earring. Hulk Labs plans to stake the NFT on NFTX vaults to earn income from this asset. CryptoPunks are a mature asset class, having completed over $2 Billion Dollars in volume to-date.
"Tokens.com is one of the only publicly traded companies to hold its own CryptoPunk," said Andrew Kiguel, CEO of Tokens.com. "Since CryptoPunks can now be staked, we have the ability to own this unique asset class and also generate recurring revenue from it. This is in line with our philosophy of holding crypto assets that can appreciate in value and generate income."
About Hulk Labs
Hulk Labs is a Tokens.com subsidiary company that invests in the NFT ecosystem with a focus on play-to-earn games. The Company acquires gaming tokens and NFTs and monetizes them through staking and gaming guilds. For further information please visit https://tokens.com.
About Tokens.com
Tokens.com Corp is a publicly traded Web3 company that owns an inventory of Metaverse, P2E, DeFi and NFT based digital assets. Tokens.com is the majority owner of Metaverse Group, one of the world’s first virtual real estate companies. Hulk Labs, a wholly-owned Tokens.com subsidiary, focuses on investing in Play-to-Earn revenue generating gaming tokens and NFTs. Additionally, Tokens.com owns and stakes crypto assets to earn additional tokens. Through its growing digital assets and NFTs, Tokens.com provides public market investors with a simple and secure way to gain exposure to Web3.
Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities at Twitter, LinkedIn, and YouTube.
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at https://www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220201005359/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
+1-647-578-7490
mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
mailto://contact@tokens.com
Media: Ryleigh Ebron – Talk Shop Media
mailto://ryleigh@talkshopmedia.com
NEWS -- Provectus Biopharmaceuticals Announces Acceptance of PV-10® Neuroendocrine Cancer Abstract for Oral Presentation at 2022 European Neuroendocrine Tumor Society (ENETS) Annual Conference
KNOXVILLE, TN, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of investigational cancer immunotherapy PV-10 (rose bengal sodium), which has completed enrollment for the treatment of neuroendocrine tumors (NET) metastatic to the liver (mNET) refractory to somatostatin analogs (SSAs) and peptide receptor radionuclide therapy (PRRT) (NCT02693067), will be presented at the annual conference of the European Neuroendocrine Tumor Society (ENETS), to be held in a hybrid setting from March 10-11, 2022 in Barcelona, Spain and online.
The abstract, which was accepted for oral presentation, is entitled:
This new item does relate to HTBX as follows:
"As previously announced, Elusys has executed a definitive merger agreement with Heat Biologics, Inc. (NASDAQ: HTBX), pursuant to which Elusys will merge into a wholly owned subsidiary of Heat. The acquisition is expected to close during the first quarter of 2022 and is subject to customary closing conditions."
A new video from FuelPositive dated 1/31/22:
https://stockhouse.com/video/thepowerplay/nxo3rdvh?mediaId=nXO3rdVh
NEWS -- FuelPositive Announces Filing of Annual Audited Financial Statements and Provides Corporate Update
Company is on schedule for demonstration project rollout in mid-2022
TORONTO, Jan. 31, 2022 (GLOBE NEWSWIRE) -- FuelPositive Corporation (TSX.V: NHHH) (OTCQB: NHHHF) (the “Company”) is pleased to announce that it has filed its annual audited financial statements and accompanying management’s discussion and analysis for the year ended September 30, 2021. Copies of the materials are available publicly under the profile for the Company on the SEDAR website (https://www.sedar.com). The Company is also pleased to provide the following update regarding ongoing business and operations.
Demonstration Prototypes
The building of the first demonstration systems for FuelPositive’s green ammonia production system is progressing to plan. The on-site system comprises a nitrogen generator to produce nitrogen from air, a water electrolyser to produce hydrogen from water, and a patent-pending green ammonia synthesis reactor to produce ammonia from the hydrogen and nitrogen.
NEWS -- Elusys Therapeutics Finalizes HHS Contract to Deliver ANTHIM®, Its Treatment for Inhalation Anthrax, to the U.S. Department of Health and Human Services
Completed first phase of contract for $50 million; HHS options to procure up to $31 million of ANTHIM by the first half of 2023
Reaffirms ANTHIM as an important medical countermeasure in the U.S. government’s strategy to maintain sufficient quantities of anthrax anti-toxin to effectively respond to an anthrax emergency
PARSIPPANY, N.J., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Elusys Therapeutics, Inc. (Elusys) announced today that it has finalized a contract with the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS) for the continued supply of ANTHIM (obiltoxaximab), an anthrax antitoxin, for use against a potential anthrax attack.
“Elusys is pleased to continue its successful track record of supplying a critical medicine to treat the deadly effects of anthrax exposure,” said Elizabeth Posillico, president and chief executive officer of Elusys. “ANTHIM is a key therapeutic in the U.S. government’s preparedness strategy to protect the U.S. population against natural and man-made biothreats.”
The contract for the procurement of ANTHIM consists of a base period of performance, valued at $50 million, which has been fulfilled. The contract includes options valued up to $31 million. If all options are exercised, the total contract value will be $80,864,000 with completion of the contract expected by the first half of 2023. Contract 75A50121C00073 is funded by HHS ASPR.
As previously announced, Elusys has executed a definitive merger agreement with Heat Biologics, Inc. (NASDAQ: HTBX), pursuant to which Elusys will merge into a wholly owned subsidiary of Heat. The acquisition is expected to close during the first quarter of 2022 and is subject to customary closing conditions.
About ANTHIM
ANTHIM is a monoclonal antibody that binds to the protective antigen (PA) component of anthrax toxin. ANTHIM’s toxin neutralizing activity prevents entry of anthrax toxin into susceptible cells, avoiding further spread of the toxin throughout the body and the ensuing tissue damage that leads to death. ANTHIM is supplied as single-dose vials for IV infusion.
ANTHIM is indicated in adult and pediatric patients for the treatment of inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate. ANTHIM should only be used for prophylaxis when its benefit for prevention of inhalational anthrax outweighs the risk of hypersensitivity and anaphylaxis. The effectiveness of ANTHIM is based solely on efficacy studies in animal models of inhalational anthrax. There have been no studies of the safety or pharmacokinetics (PK) of ANTHIM in the pediatric population. Dosing in pediatric patients was derived using a population PK approach. ANTHIM does not have direct antibacterial activity. ANTHIM should be used in combination with appropriate antibacterial drugs. ANTHIM is not expected to cross the blood-brain barrier and does not prevent or treat meningitis.
Anthrax is a life-threatening infectious disease caused by Bacillus anthracis. Cases of inhalational anthrax in humans can occur through intentional spread of B. anthracis spores as a biowarfare or bioterrorism agent. B. anthracis spores introduced through the lungs lead to inhalational anthrax, which is deadly in humans.
IMPORTANT SAFETY INFORMATION Including BOXED WARNING
WARNING: HYPERSENSITIVITY and ANAPHYLAXIS
Hypersensitivity reactions, including anaphylaxis, have been reported during ANTHIM infusion. ANTHIM should be administered in monitored settings by personnel trained and equipped to manage anaphylaxis. Stop ANTHIM infusion immediately and treat appropriately if hypersensitivity or anaphylaxis occurs.
WARNINGS AND PRECAUTIONS
Hypersensitivity and anaphylaxis have been reported during the IV infusion of ANTHIM. Due to the risk of hypersensitivity and anaphylaxis, ANTHIM should be administered in monitored settings by personnel trained and equipped to manage anaphylaxis. Monitor individuals who receive ANTHIM closely for signs and symptoms of hypersensitivity reactions throughout the infusion and for a period of time after administration. Stop ANTHIM infusion immediately and treat appropriately if hypersensitivity or anaphylaxis occurs. Pre-medication with diphenhydramine is recommended prior to administration of ANTHIM. Diphenhydramine pre-medication does not prevent anaphylaxis and may mask or delay onset of symptoms of hypersensitivity.
ADVERSE REACTIONS
The safety of ANTHIM has been studied only in healthy volunteers. It has not been studied in patients with inhalational anthrax. The most frequently reported adverse reactions were headache, pruritus, infections of the upper respiratory tract, cough, vessel puncture site bruise, infusion site swelling, urticaria, nasal congestion, infusion site pain, and pain in extremity.
USE IN SPECIFIC POPULATIONS
Pediatric Use: There have been no studies of the safety or PK of ANTHIM in the pediatric population.
To see the complete prescribing information for ANTHIM, click here (https://anthim.com/assets/pdfs/ANTHIM-prescribing-information.pdf).
About Elusys Therapeutics
Elusys, based in Parsippany, NJ, is focused on the development of antibody therapeutics for the treatment of infectious disease. ANTHIM®(obiltoxaximab) Injection, the company’s monoclonal antibody (mAb) anthrax antitoxin, received market clearance by the U.S. Food and Drug Administration (FDA) in March 2016. In July 2020, Health Canada approved ANTHIM’s New Drug Submission (NDS) for the treatment of inhalation anthrax. ANTHIM has also received marketing approved in the E.U. and the U.K., under the trade name of Obiltoxaximab SFL. For more information, please visit https://www.elusys.com.
CONTACT:
Elizabeth Posillico
Elusys Therapeutics, Inc.
t: 973.808.0222
e: mailto://eposillico@elusys.com
I hope Frank is not sick and in good health, he stops tweeting on all accounts, hopes that this will do well, A bump in the road .
NEWS -- Tokens.com Purchases Premium Waterfront Real Estate in the Somnium Space Metaverse
TORONTO, January 28, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or the "Company"), a publicly-traded company that invests in crypto assets linked to the Metaverse, Decentralized Finance ("DeFi"), Non-Fungible Tokens ("NFTs") and Play-to-Earn Gaming ("P2E"), is pleased to announce that its subsidiary, Metaverse Group (https://metaversegroup.com/), has purchased four extra large premium virtual waterfront parcels in the Somnium Space metaverse.
The premium waterfront parcels diversify Metaverse Group’s eight-figure real estate portfolio across several metaverses. The virtual real estate provides new opportunities for brands to connect with new audiences and showcase their ecommerce offerings in the metaverse. Metaverse Group’s additional parcel purchases continue to solidify its position as leading metaverse real estate owners and developers.
"We are diversifying our virtual land holdings to make navigating the metaverse more accessible to brands beginning or expanding their metaverse marketing strategies," commented Tokens.com CEO, Andrew Kiguel. "In addition, we are working to democratize all Web3 assets, making them available to the public in liquid form through our publicly traded shares. Tokens.com continues to be one of the only publicly traded companies offering such an extensive and diverse portfolio of crypto assets including the metaverse, P2E Gaming, NFTs, DeFi and staking."
Metaverse Group’s newly acquired premium parcels were strategically chosen due to their high retail value, given that they are positioned on exclusive waterfront. Much like property in the physical world, virtual lots that are positioned near water hold a higher value than those inland. Metaverse Group owns a total of 11 parcels positioned on waterfront and inland equivalent to 18,000 sq feet purchased for 58,000 CUBE, the Somnium Space native currency. Parties interested in virtual land parcels can contact mailto://landsales@metaversegroup.com.
Somnium Space is a virtual reality (VR) world built on the Ethereum blockchain. An open-source platform, Somnium Space allows users to buy digital land, homes, buildings, and myriad in-game assets of value in its online multiverse. Somnium space is compatible with Oculus Quest, a virtual reality headset. Somnium Space gained significant attention in 2021 when Tyler and Cameron Winklevoss joined the project as official advisors and made an investment through the Gemini Frontier Fund.
About Tokens.com
Tokens.com Corp is a publicly traded Web3 company that owns an inventory of Metaverse, P2E, DeFi and NFT based digital assets. Tokens.com is the majority owner of Metaverse Group, one of the world’s first virtual real estate companies. Hulk Labs, a wholly-owned Tokens.com subsidiary, focuses on investing in Play-to-Earn revenue generating gaming tokens and NFTs. Additionally, Tokens.com owns and skates crypto assets to earn additional tokens. Through its growing digital assets and NFTs, Tokens.com provides public market investors with a simple and secure way to gain exposure to Web3.
For further information please visit https://Tokens.com
Keep up-to-date on Tokens.com developments and join our online communities at Twitter, LinkedIn, and YouTube.
About Metaverse Group
The Metaverse Group is a vertically integrated NFT based metaverse real estate company. The group, with its global headquarters in Decentraland’s Crypto Valley, also owns an eight figure real estate portfolio across many leading virtual worlds. The company intends to continue to purchase, develop and rent out its portfolio of real estate assets. Tokens.com, a publicly- traded company, is the majority owner of Metaverse Group.
For further information please visit https://metaversegroup.com
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at https://www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220128005069/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
Telephone: +1-647-578-7490
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Media Contact: Ryleigh Ebron – Talk Shop Media
Email: mailto://ryleigh@talkshopmedia.com
Goldman Sachs Says the Metaverse Could Be an $8 Trillion Opportunity
Global investment bank Goldman Sachs has predicted that the metaverse could be an $8 trillion opportunity. Goldman Sachs’ analyst Eric Sheridan explained the bank’s metaverse prediction in a recent “Exchanges at Goldman Sachs” episode, titled “Understanding the metaverse and web 3.0.”
NEWS -- Provectus Biopharmaceuticals Provides Update on Research into PV-10® Immunotherapy as an Immune Adjuvant for Making Vaccines Work Better
KNOXVILLE, TN, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided an update on research of its investigational immunotherapy PV-10 (rose bengal sodium, a halogenated xanthene small molecule) as an immune adjuvant in vaccines for cancer and viruses to improve immune response upon vaccination, in conjunction with the Company’s ongoing efforts to expand its intellectual property.
On January 20, 2022, the U.S. Patent and Trademark Office (USPTO) published Provectus’ patent application entitled “Halogenated Xanthenes as Vaccine Adjuvants” (publication no. US 2022/0016242 A1), which contained among other things:
NEWS -- Oncolytics Biotech® Partner Adlai Nortye Advances to the Second Dose Escalation Cohort of the Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer
Enrollment in the first dose escalation is complete with no safety issues reported to date
Trial is designed to accelerate pelareorep's development in Asian territories such as China, the world's second-largest pharmaceutical market
SAN DIEGO, Calif. and CALGARY, AB, Jan. 27, 2022 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that its partner Adlai Nortye has advanced to the second of three dose escalation cohorts in the bridging clinical trial evaluating the safety, tolerability, and preliminary efficacy of pelareorep-paclitaxel combination therapy in Chinese patients with advanced or metastatic breast cancer. Dosing in the trial's first dose escalation cohort is complete and no safety issues have been reported. The second dose escalation cohort is the equivalent dose that was administered in the IND-213 study, which reported a near doubling of survival in HR+/HER2- metastatic breast cancer patients.
"Initiation of the bridging trial's second dose escalation cohort is an important advancement that reflects the positive safety findings observed in the trial to date," said Andrew de Guttadauro, President of Oncolytics Biotech U.S. and Global Head of Business Development. "Completion of the bridging trial will allow future Chinese regulatory submissions that will include previously reported clinical data demonstrating pelareorep's potential to substantially benefit metastatic breast cancer patients. This may accelerate pelareorep's development in rapidly growing pharmaceutical markets such as China, which is the second largest in the world after the United States. Looking ahead, we will continue to collaborate closely with Adlai Nortye to advance pelareorep towards registration in these jurisdictions and maximize its potential therapeutic impact."
The bridging clinical trial is designed to satisfy Chinese regulatory requirements and thereby accelerate pelareorep's development in territories that include China, Hong Kong, and Macau. Results from the trial are expected to allow Adlai Nortye to include data from Oncolytics' randomized North American metastatic breast cancer trials in future submissions to regulators in China and its territories.
The first of Oncolytics' randomized North American trials, IND-213, showed a statistically significant near doubling of overall survival in patients treated with pelareorep and paclitaxel compared to those treated with paclitaxel alone. Oncolytics' second randomized North American trial, BRACELET-1, is ongoing and evaluates pelareorep-paclitaxel combination therapy both with and without a checkpoint inhibitor. Oncolytics expects to complete enrollment in BRACELET-1 later this quarter and to report top-line data from the trial in Q4. Oncolytics believes completion of BRACELET-1 represents the last major clinical step on pelareorep's path to a registrational study in metastatic breast cancer in the United States.
About Breast Cancer
Breast cancer is the most common cancer in women worldwide, with over two million new cases diagnosed in 2018, representing about 25 percent of all cancers in women. It is the second leading cause of death from cancer in women in America, with an estimated 42,000 deaths in the U.S. in 20201. In China, breast cancer is now estimated to be the largest subtype of cancer among women, with over 416,000 cases and over 117,000 deaths in 20202.
Breast cancer starts when cells in the breast begin to grow out of control. These cells usually form a tumor that can often be seen on an x-ray or felt as a lump. The malignant tumor (cancer) gets worse when the cells grow into (invade) surrounding tissues or spread (metastasize) to distant areas of the body.
About Adlai Nortye
Adlai Nortye is a global clinical-stage biopharmaceutical company focused on innovative oncology drugs, with its R&D and global clinical operation centers in both China and the United States. With a strategic emphasis on oncology, the Company has built a global pipeline through collaborations and internal discovery with more than 10 drug candidates in development. Currently, four of them are being investigated in multiple clinical trials, including the FDA Fast-Track designated Buparlisib (AN2025) in a global phase III clinical trial; the FDA Fast-Track designated intravenously administered oncolytic virus pelareorep (AN1004) to have completed a phase II clinical trial; an oral EP4 antagonist (AN0025, Palupiprant) has completed Phase 1b trial in a neoadjuvant setting in locally advanced rectal cancer and is undergoing Phase 1b trial in combination with Keytruda® in patients with multiple solid tumors; an oral small molecule PD-L1 drug (AN4005) currently in Phase 1 trial that was shown to functionally overcome the inhibition derived from PD-1/L1 interaction in reporter- and human PBMC (hPBMC)-based cellular assays. In addition, the Company also completed the first patient dosing for its Phase I clinical trial in collaboration with Roche to evaluate the triple combination of AN2025, AN0025 and atezolizumab (PD-L1 inhibitor) for a variety of PIK3CA mutant solid tumors in September 2021 in the U.S.
The Company has assembled a world-class management team, built its unique immuno-oncology platforms and partnered with multiple top pharmaceutical companies to promote innovation. Adlai Nortye is committed to becoming an innovative biopharmaceutical company with global vision and strives to benefit patients worldwide. The ultimate goal of the Company is to transform cancer into manageable conditions. For more information, please visit: https://www.adlainortye.com.
About Oncolytics Biotech Inc.
Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved oncology treatments. Oncolytics is currently conducting and planning clinical trials evaluating pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies as it advances towards a registration study in metastatic breast cancer. For further information, please visit: https://www.oncolyticsbiotech.com.
References
1. "Breast Cancer Statistics and Resources." Breast Cancer Research Foundation. https://www.bcrf.org/breast-cancer-statistics-and-resources
2. Cao, Wei, et al; Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020, Chinese Medical Journal: April 5, 2021 - Volume 134 - Issue 7 - p 783-791. doi:10.1097/CM9.0000000000001474;
https://journals.lww.com/cmj/Fulltext/2021/04050/Changing_profiles_of_cancer_burden_worldwide_and.5.aspx
This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements contained in this press release include statements regarding Oncolytics' belief as to the potential and benefits of pelareorep as a cancer therapeutic; Oncolytics' expectations as to the purpose, design, outcomes and benefits of its current or pending clinical trials involving pelareorep; pelareorep's potential to substantially benefit metastatic breast cancer patients; the potential acceleration of pelareorep's development in rapidly growing pharmaceutical markets such as China; Oncolytics' plans to continue to collaborate closely with Adlai Nortye to advance pelareorep towards registration in certain jurisdictions and maximize its potential therapeutic impact; and other statements related to anticipated developments in Oncolytics' business and technologies. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics' ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. In particular, we may be impacted by business interruptions resulting from COVID-19 coronavirus, including operating, manufacturing supply chain, clinical trial and project development delays and disruptions, labour shortages, travel and shipping disruption, and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how Oncolytics may be affected if the COVID-19 pandemic persists for an extended period of time. We may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult Oncolytics' quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.
Company Contact
Jon Patton
Director of IR & Communication
+1-858-886-7813
mailto://jpatton@oncolytics.ca
Investor Relations for Oncolytics
Timothy McCarthy
LifeSci Advisors
+1-917-679-9282
mailto://tim@lifesciadvisors.com
View original content to download multimedia: https://www.prnewswire.com/news-releases/oncolytics-biotech-partner-adlai-nortye-advances-to-the-second-dose-escalation-cohort-of-the-chinese-bridging-trial-evaluating-pelareorep-paclitaxel-combination-treatment-in-breast-cancer-301469132.html
SOURCE Oncolytics Biotech® Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/January2022/27/c5674.html
NEWS -- Vivos Inc. Provides 2021 Recap and Outlines 2022 Objectives
Richland WA, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), provides 2021 recap and outlines future objectives. Vivos’ CEO, Dr. Mike Korenko stated, “as we begin 2022, we wanted to review our progress during the past year and provide insights on our thinking for 2022 and beyond.”
Highlights for 2021 include the following:
NEWS -- Lineage to Present at B. Riley Securities 2022 Virtual Oncology Conference on January 27, 2022
Fireside Chat with B. Riley Research Scheduled for 2:00pm Eastern
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will present at the B. Riley Securities 2022 Virtual Oncology Conference, in a fireside chat hosted by Mayank Mamtani, Managing Director, Senior Biotech Research Analyst and Group Head of Healthcare Research at B. Riley Securities.
Mr. Culley will provide an update on Lineage’s cell therapy pipeline, including an outline of the clinical development plans for its OPC1 program for the treatment of spinal cord injury and VAC2 for the treatment of solid tumors. Lineage recently received a $50 million upfront payment from Genentech, a member of the Roche Group, under the Company’s exclusive worldwide collaboration for the development and commercialization of OpRegen®, an RPE cell therapy for the treatment of ocular disorders. Lineage plans to use a portion of the payment to help support the advancement of its OPC1 and VAC programs noted above, as well as the expansion of its regenerative medicine platform into new disease settings which are yet to be disclosed.
Interested parties can register to view both the live event and replay on the Events and Presentations section of Lineage’s website. Additional videos are available on the Media page of the Lineage website.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic (“off-the-shelf”) product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, which is now being developed under a worldwide collaboration with Roche and Genentech, a member of the Roche Group; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic dendritic cell therapy produced from Lineage’s VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer. For more information, please visit https://www.lineagecell.com or follow the Company on Twitter @LineageCell.
Forward-Looking Statements
Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “aim,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “can,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” “contemplate,” “project,” “target,” “tend to,” or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to the collaboration and license agreement with Roche and Genentech and activities expected to occur under the collaboration and license agreement, the upfront, milestone and royalty consideration payable to Lineage and Lineage’s planned use of proceeds therefrom, the potential benefits of treatment with OpRegen, and Lineage’s plans to advance its spinal cord injury and oncology programs and announce new disease settings where it plans to deploy its technology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineage’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including the risk that competing alternative therapies may adversely impact the commercial potential of OpRegen, which could materially adversely affect the milestone and royalty payments payable to Lineage under the collaboration and license agreement, the risk that Roche and Genentech may not be successful in completing further clinical trials for OpRegen and/or obtaining regulatory approval for OpRegen in any particular jurisdiction, and risks and uncertainties inherent in Lineage’s business and other risks in Lineage’s filings with the Securities and Exchange Commission (SEC). Lineage’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading “Risk Factors” in Lineage’s periodic reports with the SEC, including Lineage’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the SEC and its other reports, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220124005033/en/
Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
(mailto://ir@lineagecell.com)
(442) 287-8963
Solebury Trout IR
Mike Biega
(mailto://Mbiega@soleburytrout.com)
(617) 221-9660
Russo Partners – Media Relations
Nic Johnson or David Schull
mailto://Nic.johnson@russopartnersllc.com
mailto://David.schull@russopartnersllc.com
(212) 845-4242
Big interview that explains a lot! SMURF $
I never heard of a situation where insiders buying their own stock was a bad thing, It shows confidence always.
Frank is buying today!
New interview !!!
I don't know if we dodged a bullet or not but the people at VNTH are metaverse schooled and they know what is hot, so when the dust clears and we get what really happened I will sit back and wait.
If that is true, that would be a problem, a controlling 51% interest is the way to go, if Frank would have given more details in all of this it would have helped all of us.
I think the liar here is the person who set this company up and promised 1 million dollars and doesn't follow through with his promise and tries to fire David because he was putting him in the light to get the money, that person that promised invested the money in RBLX and so far lost 20% of the money If he was true to his word this stock would be at over a penny by now and even higher with the Korean deal that CEO David had ready to go.
NEWS -- Oncolytics Biotech® Provides Enrollment Update on Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium
SAN DIEGO, Calif. and CALGARY, Canada, Jan. 20, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) provided an enrollment update on the phase 1/2 GOBLET study in a poster presentation at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI).
The GOBLET study is being managed by AIO, a leading academic cooperative medical oncology group based in Germany, and is designed to evaluate the safety and efficacy of pelareorep in combination with Roche's anti-PD-L1 checkpoint inhibitor atezolizumab in patients with metastatic pancreatic, metastatic colorectal, and advanced anal cancers. The study includes three-patient safety run-ins for two of its four cohorts (first-line metastatic pancreatic and third-line metastatic colorectal cancer). Enrollment in these safety run-ins is complete. The study remains ongoing and is expected to enroll patients at 14 clinical trial sites across Germany.
"There is a pressing unmet need for agents that can synergize with immune checkpoint inhibitors (ICI) in gastrointestinal (GI) cancers, as fewer than half of these patients respond to ICI monotherapy," said Dirk Arnold M.D., Ph.D., Director of Asklepios Tumorzentrum Hamburg, and primary investigator of the GOBLET trial. "These low response rates are driven by immunosuppressive tumor microenvironments, which pelareorep has been shown to reverse in prior clinical studies in GI, breast, and hematological cancers. We thus believe pelareorep can increase the proportion of GI cancer patients responding to checkpoint inhibitors and are seeking to validate this hypothesis in the GOBLET study. We are very pleased with the trial's progress to date and look forward to its continued advancement."
The GOBLET study builds on previously reported clinical proof-of-concept data for pelareorep-checkpoint inhibitor combination therapy in pancreatic cancer (link to PR, link to poster). It is also supported by prior early clinical data showing that pelareorep-based combination treatments stimulated an adaptive immune response and led to a greater than 90% clinical benefit rate in KRAS-mutated colorectal cancer patients (link to PR, link to study) and a greater than 80% increase in progression-free survival in pancreatic cancer patients with low levels of CEACAM6 expression (link to PR, link to poster). In addition to evaluating the safety and efficacy of pelareorep-atezolizumab treatment, the study also seeks to demonstrate the potential of CEACAM6 and T cell clonality as predictive biomarkers, which may allow selection of the most appropriate patients in future registration studies and increase their likelihood of success.
A copy of the ASCO-GI poster titled, "GOBLET: A phase 1 / 2 multiple-indication biomarker, safety, and efficacy study in advanced or metastatic gastrointestinal cancers exploring treatment combinations with pelareorep and atezolizumab," will be available on the Posters & Publications page of Oncolytics' website (LINK) following the conclusion of the symposium.
About GOBLET
The GOBLET (Gastrointestinal tumOrs exploring the treatment comBinations with the oncolytic reovirus peLarEorep and anTi-PD-L1) study is a phase 1/2 multiple indication study in advanced or metastatic gastrointestinal tumors. The study is being conducted at 14 centers in Germany. The co-primary endpoints of the study are objective response rate (ORR) assessed at week 16 and safety. Key secondary and exploratory endpoints include additional efficacy assessments and evaluation of potential biomarkers (T cell clonality and CEACAM6). The study employs a Simon two-stage design with Stage 1 comprising four treatment groups expected to enroll a total of approximately 55 patients:
$VNTH David is fighting the good fight , Frank promised 1 million infusions in VNTH , Frank is Goliath , David got the SEC rock in his slingshot. David fighting for his CEO position.
New tweeter Nano Mobile
@NanoTechCrypto
$VNTH Mr. Igwealor did not have the rights to make the SEC filing regarding the company this morning. He was not the CEO, on the Board of Directors or even a majority shareholder. Mr. Igwealor made many promises we had been patiently waiting for him to deliver. @EdgarInsider
8:24 AM · Jan 18, 2022·Twitter for iPhone
If Mr.David twittle is out as CEO is he still working at VNTH because there were twits after the CEO was let go . And maybe he is still with the team as a metaverse consultant or designer.
A company filing came out this morning stating that the 18-year old CEO, David Kittle, is no longer with them.
-------------
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.
On January 14, the Company parted ways with Mr. David Noah Kittle, who was previously appointed President and CEO of the Company on October 14, 2021. Mr. Kittle's departure was not the result of any dispute or disagreement with the Company or the Company's Board of Directors on any matter relating to the operations, policies or practices of the Company. The Company needed a jolt and change of leadership to help it capitalize on emerging opportunities in the Web3, Gaming, Crypto and Metaverse industries. The Company has begun a search for a new President and CEO.
-------------
I also saw a message on another board that said that Frank is not authorized to post such news.
It's getting interesting here, folks!
NEWS -- Tokens.com Launches Crypto Play-to-Earn Gaming and NFT Investment Platform
TORONTO, January 18, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or the "Company"), a publicly-traded company that invests in crypto assets linked to the Metaverse, Decentralized Finance ("DeFi"), and Non-Fungible Tokens ("NFTs"), is pleased to announce it has launched Hulk Labs, a new wholly-owned subsidiary focused on investing in Play-to-Earn revenue generating gaming tokens and NFTs.
Hulk Labs represents a new Web3 vertical for Tokens.com focused on the lucrative Play-to-Earn (P2E) sector. Alongside its crypto staking and Metaverse operations, Hulk Labs provides exposure to the gaming and NFT sectors for Tokens.com shareholders.
Hulk Labs will be led by Tokens.com’s COO, Deven Soni, an experienced executive and investor, along with a founding team including Ben Yu, a prominent influencer and educator in the blockchain space and Joshua Doner, an active blockchain investor who was one of the first people to ever purchase an NFT.
"Tokens.com is focused on bringing the most exciting growth areas of Web3 and crypto to its investors," said Andrew Kiguel, CEO, Tokens.com. "We are excited to enter into this new vertical with an outstanding team. We have successfully provided our investors with exposure to assets linked to the Metaverse, DeFi, and NFTs. This next stage in our evolution adds gaming and positions us uniquely as one of the only public companies to offer a complete range of Web3 exposure."
P2E gaming is the next major opportunity in Web3 and blockchain. It merges the engagement and entertainment value of online gaming, a sector with 400M+ global daily users, and the ability to earn real-world income through the combination of digital asset ownership and gameplay. This sector was popularized by Axie Infinity, which has 3M+ daily active users and a fully diluted market cap of $20Bn+. The sector has grown dramatically in the last 2 quarters to encompass 600+ games and billions of dollars of crypto market cap. Tokens.com’s CEO, Andrew Kiguel has previously commented on the strength of crypto gaming in Business Insider (https://www.businessinsider.com/how-to-invest-in-axie-infinity-play-to-earn-gaming).
As part of the launch, Hulk Labs is announcing initial investments in several high-potential NFT projects including Illuvium (an open world RPG game based on the Ethereum blockchain), NFTX (a platform for creating liquid markets in illiquid NFTs), and Wall Street Bulls (a gamified NFT collection inspired by retail traders). Tokens.com will also transfer its ownership of 833 million Shiba Inu tokens to Hulk Labs.
Hulk Labs will continue to proactively acquire and monetize assets in the P2E and NFT sectors. The Company plans to monetize its assets by staking its token holdings and by depositing its gaming P2E assets into top game guilds which loan NFT assets to players in exchange for a revenue share of their gameplay earnings.
"I’m excited to partner with Tokens.com, collaborate with them as they expand into the NFT sector, and give their public market investors access to these innovative and rapidly growing assets," commented Hulk Labs Co-Founder, Ben Yu.
Additionally, Tokens.com would like to welcome Joshua Doner who has joined the team as Chief NFT Officer. Josh has 6 years of crypto related experience, having transacted and owned various types of assets on many of the top Crypto/Defi protocols and platforms. Josh is an investor, advisor and contributor to various startups and DAOs operating in Crypto.
About Tokens.com
Tokens.com Corp is a publicly traded company that invests in Web3 assets - the Metaverse, DeFi and NFTs. Through a process called staking, Tokens.com’s inventory of crypto assets are used to earn additional tokens. In addition, Tokens.com is the majority owner of the Metaverse Group, one of the world’s first virtual real estate companies. Through its growing digital assets and NFTs, Tokens.com provides public market investors with a simple and secure way to gain exposure to Web3.
For further information please visit https://Tokens.com
Keep up-to-date on Tokens.com developments and join our online communities at Twitter, LinkedIn, and YouTube.
About Hulk Labs
Hulk Labs is a Tokens.com subsidiary company that invests in the NFT ecosystem with a focus on play-to-earn games. The Company acquires gaming tokens and NFTs and monetizes them through staking and gaming guilds. For further information please visit https://tokens.com .
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220118005489/en/
Contacts
For further information, please contact:
Tokens.com Corp.
Andrew Kiguel, CEO
Telephone: +1-647-578-7490
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Media Contact: Ryleigh Ebron – Talk Shop Media
Email: mailto://ryleigh@talkshopmedia.com
NEWS -- Tokens.com Launches Crypto Play-to-Earn Gaming and NFT Investment Platform
TORONTO, January 18, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or the "Company"), a publicly-traded company that invests in crypto assets linked to the Metaverse, Decentralized Finance ("DeFi"), and Non-Fungible Tokens ("NFTs"), is pleased to announce it has launched Hulk Labs, a new wholly-owned subsidiary focused on investing in Play-to-Earn revenue generating gaming tokens and NFTs.
Hulk Labs represents a new Web3 vertical for Tokens.com focused on the lucrative Play-to-Earn (P2E) sector. Alongside its crypto staking and Metaverse operations, Hulk Labs provides exposure to the gaming and NFT sectors for Tokens.com shareholders.
Hulk Labs will be led by Tokens.com’s COO, Deven Soni, an experienced executive and investor, along with a founding team including Ben Yu, a prominent influencer and educator in the blockchain space and Joshua Doner, an active blockchain investor who was one of the first people to ever purchase an NFT.
"Tokens.com is focused on bringing the most exciting growth areas of Web3 and crypto to its investors," said Andrew Kiguel, CEO, Tokens.com. "We are excited to enter into this new vertical with an outstanding team. We have successfully provided our investors with exposure to assets linked to the Metaverse, DeFi, and NFTs. This next stage in our evolution adds gaming and positions us uniquely as one of the only public companies to offer a complete range of Web3 exposure."
P2E gaming is the next major opportunity in Web3 and blockchain. It merges the engagement and entertainment value of online gaming, a sector with 400M+ global daily users, and the ability to earn real-world income through the combination of digital asset ownership and gameplay. This sector was popularized by Axie Infinity, which has 3M+ daily active users and a fully diluted market cap of $20Bn+. The sector has grown dramatically in the last 2 quarters to encompass 600+ games and billions of dollars of crypto market cap. Tokens.com’s CEO, Andrew Kiguel has previously commented on the strength of crypto gaming in Business Insider (https://www.businessinsider.com/how-to-invest-in-axie-infinity-play-to-earn-gaming).
As part of the launch, Hulk Labs is announcing initial investments in several high-potential NFT projects including Illuvium (an open world RPG game based on the Ethereum blockchain), NFTX (a platform for creating liquid markets in illiquid NFTs), and Wall Street Bulls (a gamified NFT collection inspired by retail traders). Tokens.com will also transfer its ownership of 833 million Shiba Inu tokens to Hulk Labs.
Hulk Labs will continue to proactively acquire and monetize assets in the P2E and NFT sectors. The Company plans to monetize its assets by staking its token holdings and by depositing its gaming P2E assets into top game guilds which loan NFT assets to players in exchange for a revenue share of their gameplay earnings.
"I’m excited to partner with Tokens.com, collaborate with them as they expand into the NFT sector, and give their public market investors access to these innovative and rapidly growing assets," commented Hulk Labs Co-Founder, Ben Yu.
Additionally, Tokens.com would like to welcome Joshua Doner who has joined the team as Chief NFT Officer. Josh has 6 years of crypto related experience, having transacted and owned various types of assets on many of the top Crypto/Defi protocols and platforms. Josh is an investor, advisor and contributor to various startups and DAOs operating in Crypto.
About Tokens.com
Tokens.com Corp is a publicly traded company that invests in Web3 assets - the Metaverse, DeFi and NFTs. Through a process called staking, Tokens.com’s inventory of crypto assets are used to earn additional tokens. In addition, Tokens.com is the majority owner of the Metaverse Group, one of the world’s first virtual real estate companies. Through its growing digital assets and NFTs, Tokens.com provides public market investors with a simple and secure way to gain exposure to Web3.
For further information please visit https://Tokens.com
Keep up-to-date on Tokens.com developments and join our online communities at Twitter, LinkedIn, and YouTube.
About Hulk Labs
Hulk Labs is a Tokens.com subsidiary company that invests in the NFT ecosystem with a focus on play-to-earn games. The Company acquires gaming tokens and NFTs and monetizes them through staking and gaming guilds. For further information please visit https://tokens.com .
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220118005489/en/
Contacts
For further information, please contact:
Tokens.com Corp.
Andrew Kiguel, CEO
Telephone: +1-647-578-7490
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Media Contact: Ryleigh Ebron – Talk Shop Media
Email: mailto://ryleigh@talkshopmedia.com